Design and synthesis of phosphinic acids that triply inhibit endothelin converting enzyme, angiotensin converting enzyme and neutral endopeptidase 24.11

Bioorganic and Medicinal Chemistry Letters

Volumn 6, Issue 14, 1996, Pages 1629-1634

  McKittrick, Brian A ^a   Stamford, Andrew W ^a   Weng, Xiaoyu ^a   Ma, Ke ^a   Chackalamannil, Samuel ^a   Czarniecki, Michael ^a   Cleven, Reneé M ^a   Fawzi, Ahmad B ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIN CONVERTING ENZYME; ENZYME INHIBITOR; MEMBRANE METALLOENDOPEPTIDASE; PHOSPHINIC ACID DERIVATIVE;

ARTICLE; CARDIOVASCULAR DISEASE; DRUG DESIGN; DRUG SYNTHESIS; ENZYME INHIBITION; HYPERTENSION; NUCLEAR MAGNETIC RESONANCE; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

EID: 0030598676     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0960-894X(96)00297-1     Document Type: Article

References (28)

1. 1. Yanagisawa, M.; Kurihara, H.; Kimura, S.; Tomobe, Y.; Kobayashi, M.; Mitsui, Y.; Yazaki, Y.; Goto, K.; Masaki, T. Nature 1988, 332, 411.
2. 2. Reviews: Rubanyi, G. M.; Polokoff, M. A. Pharmacol. Rev. 1994, 46, 325. Doherty, A. M. J. Med. Chem., 1992, 35, 1493. Rubanyi, G. M. Drugs Fut. 1992, 17, 915.
3. 2. Reviews: Rubanyi, G. M.; Polokoff, M. A. Pharmacol. Rev. 1994, 46, 325. Doherty, A. M. J. Med. Chem., 1992, 35, 1493. Rubanyi, G. M. Drugs Fut. 1992, 17, 915.
4. 2. Reviews: Rubanyi, G. M.; Polokoff, M. A. Pharmacol. Rev. 1994, 46, 325. Doherty, A. M. J. Med. Chem., 1992, 35, 1493. Rubanyi, G. M. Drugs Fut. 1992, 17, 915.
5. 3. Review: Opgenorth, T. J.; Wu-Wong, J. R.; Shiosaki, K. FASEB 1992, 6, 2653.
6. 4. Matsamura, Y.; Hisaki, K.; Takaoka, M.; Morimoto, S. Euro. J. Pharmacol. 1990, 185, 103.
7. 5. Ikegawa, R.; Matsumura, Y.; Tsukahara, Y.; Takaoka, M.; Morimoto, S. Biochem. Biophys. Res. Commun. 1990, 171, 669.
8. 6. Xu. D.; Emoto, N.; Giaid, A.; Slaughter, C.; Kaw, S.; deWit, D.; Yanagisawa, M. Cell 1994, 78, 473.
9. 7. Vemulapalli, S.; Rivelli, M.; Chiu, P. J. S.; del Prado, M.; Hey, J. A. J. Pharmacol. Exp. Ther. 1992, 262, 1062.
10. 8. (a) Fawzi, A. B.; Cleven, R. M.; Wright, D. L. Anal. Biochem. 1994, 222, 342;
11. (b) Purified guinea pig lung ECE: Fawzi, A. B.; Wright, D. L.; Cleven, R. M.; Zhang, H. FASEB, 1994, 8, A1372.
12. 9. While this work was in progress, studies reporting inhibition of metalloprotease ECE activity appeared: Bertenshaw, S. R.; Rogers, R. S.; Stern, M. K.; Norman, B. H.; Moore, W. M.; Jerome, G. M.; Branson, L. M.; McDonald, J. F.; McMahon, E. G.; Palomo, M. A. J. Med. Chem. 1993, 36, 173. Bertenshaw, S. R.; Talley, J. R.; Rogers, R. S.; Carter, J. S.; Moore, W. M.; Branson, L. M.; Koboldt, C. M. Bioorg. Med. Chem. Lett. 1993, 3, 1953. Fukami, T.; Hayama, T.; Amano, Y.; Nakamura, Y.; Arai, Y; Matsuyama, K.; Yano, M.; Ishikawa, K. Bioorg. Med. Chem. Lett. 1994, 4, 1257. Bihovsky, R.; Levinson, B. L.; Loewi, R. C.; Erhardt, P. W.; Polokoff, M. A. J. Med. Chem. 1995, 38, 2119.
13. 9. While this work was in progress, studies reporting inhibition of metalloprotease ECE activity appeared: Bertenshaw, S. R.; Rogers, R. S.; Stern, M. K.; Norman, B. H.; Moore, W. M.; Jerome, G. M.; Branson, L. M.; McDonald, J. F.; McMahon, E. G.; Palomo, M. A. J. Med. Chem. 1993, 36, 173. Bertenshaw, S. R.; Talley, J. R.; Rogers, R. S.; Carter, J. S.; Moore, W. M.; Branson, L. M.; Koboldt, C. M. Bioorg. Med. Chem. Lett. 1993, 3, 1953. Fukami, T.; Hayama, T.; Amano, Y.; Nakamura, Y.; Arai, Y; Matsuyama, K.; Yano, M.; Ishikawa, K. Bioorg. Med. Chem. Lett. 1994, 4, 1257. Bihovsky, R.; Levinson, B. L.; Loewi, R. C.; Erhardt, P. W.; Polokoff, M. A. J. Med. Chem. 1995, 38, 2119.
14. 9. While this work was in progress, studies reporting inhibition of metalloprotease ECE activity appeared: Bertenshaw, S. R.; Rogers, R. S.; Stern, M. K.; Norman, B. H.; Moore, W. M.; Jerome, G. M.; Branson, L. M.; McDonald, J. F.; McMahon, E. G.; Palomo, M. A. J. Med. Chem. 1993, 36, 173. Bertenshaw, S. R.; Talley, J. R.; Rogers, R. S.; Carter, J. S.; Moore, W. M.; Branson, L. M.; Koboldt, C. M. Bioorg. Med. Chem. Lett. 1993, 3, 1953. Fukami, T.; Hayama, T.; Amano, Y.; Nakamura, Y.; Arai, Y; Matsuyama, K.; Yano, M.; Ishikawa, K. Bioorg. Med. Chem. Lett. 1994, 4, 1257. Bihovsky, R.; Levinson, B. L.; Loewi, R. C.; Erhardt, P. W.; Polokoff, M. A. J. Med. Chem. 1995, 38, 2119.
15. 9. While this work was in progress, studies reporting inhibition of metalloprotease ECE activity appeared: Bertenshaw, S. R.; Rogers, R. S.; Stern, M. K.; Norman, B. H.; Moore, W. M.; Jerome, G. M.; Branson, L. M.; McDonald, J. F.; McMahon, E. G.; Palomo, M. A. J. Med. Chem. 1993, 36, 173. Bertenshaw, S. R.; Talley, J. R.; Rogers, R. S.; Carter, J. S.; Moore, W. M.; Branson, L. M.; Koboldt, C. M. Bioorg. Med. Chem. Lett. 1993, 3, 1953. Fukami, T.; Hayama, T.; Amano, Y.; Nakamura, Y.; Arai, Y; Matsuyama, K.; Yano, M.; Ishikawa, K. Bioorg. Med. Chem. Lett. 1994, 4, 1257. Bihovsky, R.; Levinson, B. L.; Loewi, R. C.; Erhardt, P. W.; Polokoff, M. A. J. Med. Chem. 1995, 38, 2119.
16. 10. Kam, C.-M.; Nishino, N.; Powers, J. C. Biochemistry 1979, 18, 3032. Compound 2 was prepared as the trilithium salt.
17. 11. Danilewicz, J. C.; James, K.; Kobylecki, R. J. European Patent Application 358,398A1, 1989.
18. 12. Dingwall, J. G.; Ehrenfreund, J.; Hall, R. G. Tetrahedron 1989, 45, 3787.
19. 14 phosphonic acids I and II and correlation of the rotations. (For 5b and 5c c 1.0, EtOH; for I and II c 1.0, 1.0 M NaOH): (formula presented)
20. 14. Hanessian, S.; Bennani, Y. L. Tetrahedron Lett. 1990, 31, 6465.
21. 15. Neustadt, B. R.; Smith, E. M.; Nechuta, T. L.; Bronnenkant, A. A.; Haslanger, M. F.; Watkins, R. W.; Foster, C. J.; Sybertz, E. J. J. Med. Chem. 1994, 37, 2461.
22. 16. Morgan, P. B.; Scholtz, J. M.; Ballinger, M. D.; Zipkin, I. D.; Bartlett, P. A. J. Am. Chem. Soc. 1991, 113, 297.
23. 6P: C, 62.02; H, 6.34; N, 3.14; P, 6.95. Found: C, 62.24; H, 6.09; N, 3.25; P, 6.97.
24. 18. Fawzi, A. B.; McKittrick, B. A.; Stamford, A. W.; Wright, D. L. unpublished results.
25. 19. Cushman, D. W.; Cheung, H. S.; Biochem. Pharmacol. 1971, 20, 1637.
26. 20. Sybertz, E. J.; Chui, P. J. S.; Vemulapalli, S.; Pitts, B; Foster, C. J.; Watkins, R. W.; Barnett, A.; Haslanger, M. F. J. Pharmacol. Exp. Ther. 1989, 250, 624.
27. 21. Several groups have reported the development of dual inhibitors of ACE and NEP for the treatment of hypertension and congestive heart failure. For example, see Fink, C. A.; Qiao, Y.; Berry, C. J.; Sakane, Y.; Ghai, R. D.; Trapani, A. J. J. Med. Chem. 1995, 38, 5023 and references therein.
28. 22. In vivo activity of 4g will be reported separately.